Table 2.
Changes in waist circumference (WC) and HDL-cholesterol in women and men following daily intervention for four weeks with the placebo (PLB) drink, the polyphenol low-dose chokeberry juice (AMJd), and the polyphenol high-dose chokeberry juice (AMJ).
| PLB (n = 14) | AMJd (n = 21) | AMJ (n = 17) | p-Value (between Groups) | |
|---|---|---|---|---|
| Women | ||||
| WC (cm) | ||||
| Baseline | 87.00 (19.00) | 83.00 (15.50) | 85.00 (27.50) | 0.86 |
| End of trial | 86.00 (24.25) | 83.00 (15.50) | 88.00 (24.00) | 0.72 |
| Δ (Δ%) | −1.50 (−1.75%) | −1.00 (−1.25%) | −1.00 (−1.10%) | 0.78 |
| p-value (intragroup) | 0.09 | 0.07 | 0.28 | |
| HDL-C (mmol/L) | ||||
| Baseline | 1.87 (0.52) | 1.74 (0.64) | 1.79 (0.63) | 0.52 |
| End of trial | 1.72 (0.52) | 1.63 (0.61) | 1.66 (0.67) | 0.57 |
| Δ (Δ%) | −0.09 (−4.48%) | −0.16 (−8.74%) | −0.03 (−1.41%) | 0.18 |
| p-value (intragroup) | 0.21 | 0.02 | 0.42 | |
| T-C/HDL-C | ||||
| Baseline | 3.13 (1.35) | 2.96 (0.78) | 3.02 (1.70) | 0.77 |
| End of trial | 3.21 (1.03) | 3.21 (1.51) | 3.12 (1.55) | 0.86 |
| Δ (Δ%) | 0.08 (2.74%) | 0.14 (7.10%) | −0.03(−1.53%) | 0.26 |
| p-value (intragroup) | 0.64 | 0.11 | 0.59 | |
| LDL-C/HDL-C | ||||
| Baseline | 2.19 (1.02) | 1.94 (0.83) | 1.85 (1.48) | 0.83 |
| End of trial | 2.17 (0.96) | 1.90 (1.13) | 2.03 (1.14) | 0.79 |
| Δ (Δ%) | 0.13 (6.39%) | 0.11 (6.50%) | −0.03 (−1.25%) | 0.48 |
| p-value (intragroup) | 0.55 | 0.16 | 0.87 | |
| PLB (n = 15) | AMJd (n = 7) | AMJ (n = 10) | p-Value (between Groups) | |
| Men | ||||
| WC (cm) | ||||
| Baseline | 101.00 (11.00) | 109.00 (9.00) | 100.00 (16.00) | 0.36 |
| End of trial | 100.50 (15.71) | 105.00 (18.00) | 99.00 (15.25) | 0.45 |
| Δ (Δ%) | −1.00 (−0.99%) | −1.00 (−0.98%) | −2.00 (−1.91%) | 0.88 |
| p-value (intragroup) | 0.04 | 0.38 | 0.08 | |
| HDL-C (mmol/L) | ||||
| Baseline | 1.25 (0.27) | 1.60 (0.71) | 1.47 (0.46) | 0.21 |
| End of trial | 1.18 (0.30) | 1.45 (0.46) | 1.47 (0.70) | 0.31 |
| Δ (Δ%) | −0.07 (−4.82%) | −0.10 (−6.25%) | −0.04 (−2.45%) | 0.68 |
| p-value (intragroup) | 0.03 | 0.11 | 0.44 | |
| T-C/HDL-C | ||||
| Baseline | 4.01 (2.21) | 3.26 (0.99) | 4.04 (1.95) | 0.40 |
| End of trial | 4.40 (1.79) | 3.89 (1.02) | 4.24 (2.36) | 0.31 |
| Δ (Δ%) | 0.43 (9.69%) | 0.33 (9.40%) | −0.04 (−1.76%) | 0.80 |
| p-value (intragroup) | 0.06 | 0.31 | 0.72 | |
| LDL-C/HDL-C | ||||
| Baseline | 2.84 (1.74) | 2.34 (0.52) | 2.86 (1.36) | 0.31 |
| End of trial | 3.11 (1.35) | 2.54 (1.01) | 3.10 (2.12) | 0.38 |
| Δ (Δ%) | 0.25 (8.77%) | 0.27 (13.19%) | 0.23 (8.90%) | 0.96 |
| p-value (intragroup) | 0.27 | 0.31 | 0.33 | |
Results are presented as the median (IQR); Δ: median of (end-baseline) values; Δ%: median of ((end-baseline values)/baseline) × 100. WC: waist circumference; T-C; total cholesterol; HDL-C: high-density lipoprotein (HDL) cholesterol. Between groups differences were estimated by the non-parametric test of Kruskal-Wallis and intragroup differences by the Wilcoxon signed rank test.